7Sajid M,Stouffer GA.The role of alpha(v)beta3integrins in vascular healing. Thrombosis and Haemostasis . 2002
8Wu K,Wang C,D,Amico M,et al.Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells:association with selective cooperative inhibition ofcyclin D1-dependent kinase and Akt signaling pathways. Mol- Cancer-Ther . 2002
9K. Temming,R.M. Schiffelers,G. Molema.RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resistance Updates . 2005
4Johnston SR, Leary A. Lapatinib: a novel EGFR/Her2 tyrosine kinase inhibitor for cancer. Drugs Today ( Barc), 2006, 42:441- 453.
5Lackey KE. Lessons from the drug discovery of lapatinib, a dual ErbBl/2 tyrosine kinase inhibitor. Curr Top Med Chem, 2006, 6:435-460.
6Nelson MH, Dolder CR. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother, 2006, 40 : 261-269.
7Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumorderived cell lines in vitro and in vivo. Mol Cancer Ther, 2001, 1 : 85-94.
8Xia W, Liu LH, Ho P, et al. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene, 2004, 23:646-653.
9Xia W, Gerard CM, Liu L, et al. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene, 2005, 24: 6213-6221.
10Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against Her-2- overexpressing and trastuzumab-treated breast cancer cells. Cancer Res, 2006, 66:1630-1639.
